Related Experiment Video
Updated: Jun 5, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Regulatory and policy issues for T1DM immunotherapy.
1Kinexum, CEO, Harper's Ferry, WV, USA. zanfleming@kinexum.com
Human Vaccines
|January 19, 2011
Summary
Immunotherapies for Type 1 Diabetes (T1DM) are advancing, focusing on endogenous insulin secretion via C-peptide measurements. Future treatments will likely combine therapies for both new onset and established T1DM.
Area of Science:
- Endocrinology and Immunology
- Pharmaceutical Development
Background:
- Immunotherapy development for Type 1 Diabetes (T1DM) has historically lagged behind Type 2 Diabetes (T2DM) treatments.
- Increased regulatory clarity and expert consensus are now driving pharmaceutical investment in late-stage T1DM programs.
Purpose of the Study:
- To outline the evolving landscape of T1DM immunotherapies, focusing on regulatory expectations and therapeutic strategies.
- To highlight the consensus on primary efficacy endpoints and emerging frontiers in T1DM treatment development.
Main Methods:
- Analysis of regulatory convergence and expert opinions on assessing immunotherapy efficacy in T1DM.
- Review of current therapeutic development efforts targeting new onset and established T1DM populations.
- Consideration of future directions, including combination therapies and preventative vaccines.
Main Results:
- Agreement among regulators and experts establishes endogenous insulin secretion (C-peptide) as the primary efficacy endpoint for T1DM immunotherapies.
- Secondary endpoints include glycemic control, insulin dose reduction, and hypoglycemia rates.
- Therapeutic development is shifting towards combination treatments for established T1DM, a larger patient group.
Conclusions:
- Standardized C-peptide measurements are crucial for evaluating T1DM immunotherapies.
- Combination therapies are anticipated to be essential for effective T1DM treatment, addressing both new onset and established disease.
- Preventative vaccines for T1DM require prior successful treatment experience.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...